Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of lunsekimig in high-risk adults with asthma not currently eligible for biologic therapy
MOH_2025-01-09_013831Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Dec 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Lunsekimig + ICS/LABA with Placebo + ICS/LABA (2 arms). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2025-01-09_013831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-09_013831.